Clinical Trial Update: An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a single dose of P-552 for oral mucosal wetness in xerostomia and Sjogren's syndrome. Study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome
• Xerostomia

Drugs mentioned

• P-552

Snippet

Sponsor: Parion Sciences | Conditions: Xerostomia, Sjogren's Syndrome | Phase 1, Phase 2 | Status: COMPLETED